Dr. Phil Barker is a molecular biologist and biochemist at the Montreal Neurological Institute (MNI), and James McGill Professor in the Departments of Neurology and Neurosurgery and Anatomy and Cell Biology at McGill University.
Dr. Barker obtained his PhD in 1991 from the University of Alberta. He performed postdoctoral studies at Stanford University with Dr. Eric Shooter before joining the faculty at the Montreal Neurological Institute of McGill University in Montreal in 1994.
Dr. Barker's research program is concerned with how extracellular cues translate into intracellular signaling pathways that regulate life and death decisions in neurons and cancer cells. The Barker Lab uses several different models systems issues in neurotrophin and cytokine signaling pathways and to decipher their physiological roles.
Dr. Barker is a founder of Aegera Therapeutics Inc.; has developed and licensed several technologies to major pharmaceutical firms; and is a consultant to the biotechnology industry. From 2007 to 2011, he was the Associate Director for Strategic Initiatives at the MNI and Chair of the MNI Centre for Commercialization and Research – a $15-million fund designed to facilitate rapid translation of research into commercial ventures and clinical practice. Since 2011, Dr. Barker has been Director of the McGill Centre for Biomedical Innovation. He also served as the MNI's Interim Director from from June 2011 until December 2012, when he assumed the role of Scientific Director.